Sector Expert: Keay Nakae

Chardan Capital Markets

Keay Nakae is a senior research analyst at Chardan Capital Markets. He has fifteen years of experience as a healthcare equity research analyst and has covered small- to large-cap biotechnology, medical device and diagnostic companies that compete in areas of cardiology, gynecology, neurology, urology, oncology, diabetes, aesthetics and cardiac and spine surgery. Prior to joining Chardan, Nakae was a senior research analyst at Ascendiant Capital Markets, Collins Stewart, CE Unterberg, Towbin and Wedbush Morgan Securities. He has made media appearances on Bloomberg, and has been quoted in The Wall Street Journal, Time, Business Week and The Los Angeles Times. He has also been recognized by Forbes magazine in its annual survey of America’s Best Analysts. Before becoming an equity research analyst, Nakae worked at Atlantic Richfield Co. in corporate finance and portfolio management positions, and at St. Jude Medical as a member of the research and development engineering team responsible for the Affinity pacemaker. He earned a master's degree in business administration from UCLA's Anderson School of Management, and holds master's and bachelor's degrees in electronic engineering from Cal Poly. Nakae is a Chartered Financial Analyst (CFA) and member of the CFA Institute. He maintains FINRA Series 7, 16, and 66, 86, and 87 securities registrations.



Recent Interviews

Four Small-Cap Growth Names with Different Value Drivers: Keay Nakae (9/19/13)

keay82It's important to take the emotion out of investing. Keay Nakae, senior research analyst with Ascendiant Capital Markets, looks at micro- and small-cap biotech stocks from an engineer's perspective: It's all about the data. In this interview with The Life Sciences Report, Nakae reports on four companies with upcoming catalysts that potentially position them for significant growth—and the ability to grab investors' attention.

Recent Quotes

"There is upside to MSLP relative to the current price."

— Keay Nakae, Ascendiant Capital Markets (11/17/14)
more >

"MSLP is moving toward sustained profitability; there is upside to it."

— Keay Nakae, Ascendiant Capital Markets (8/5/14)
more >

"Initial data from STEM's Phase 1/2 AMD trial are very encouraging."

— Keay Nakae, Ascendiant Capital Markets (6/19/14)
more >

"There is upside to MSLP relative to the current price."

— Keay Nakae, Ascendiant Capital Markets (5/7/14)
more >

"Enrollment in STEM's two phase 1/2 clinical studies has picked up."

— Keay Nakae, Ascendiant Capital Markets (3/13/14)
more >

"The BARDA contract remains the key catalyst for CYTX."

— Keay Nakae, Ascendiant Capital Markets (3/12/14)
more >

"Given MSLP's current stock price and market capitalization, management intends to uplist the stock to NASDAQ."

— Keay Nakae, Ascendiant Capital Markets (1/2/14)
more >

"SYN is positioned to announce topline study data in around mid-2014."

— Keay Nakae, Ascendiant Capital Markets (11/15/13)
more >



Due to permission requirements, not all quotes are shown.